Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
FASN-IN-3
Cat. No.:
OB0225LY-0013
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
FASN-IN-3 is a poency inhibitor of fatty acid synthase (FASN).
Synonym:
2097262-60-5; FASN inhibitor 1; 4-(1-(5-(3,4-Dimethyl-1H-pyrazol-5-yl)-2,4-dimethylbenzoyl)azetidin-3-yl)benzonitrile; 4-[1-[5-(4,5-dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl]-3-azetidinyl]-benzonitrile; 4-[1-[5-(4,5-Dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl]azetidin-3-yl]benzonitrile; 4-(1-(5-(4,5-Dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl)azetidin-3-yl)benzonitrile; 4-{1-[5-(4,5-Dimethyl-2H-pyrazol-3-yl)-2,4-dimethyl-benzoyl]-azetidin-3-yl}-benzonitrile
CAS No.:
2097262-60-5
Compound CID:
72947731
Formula:
C24H24N4O
Formula Weight:
384.47
Specification
Relative Density:
1.26 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
FASN-IN-3 is essential for de novo lipogenesis and tumor growth.
Library Information
Targets:
Fatty acid synthesis
Receptors:
Fatty acid synthase
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
b4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
33.33 mg/mL; 86.69 mM
